李冠乔 - 清华大学 - 万科公共卫生与健康学院

个人简介

教育经历 2009 - 2017 医学博士，临床医学（八年制），清华大学医学院 2009 – 2012 理学学士，生命科学，清华大学生命科学学院工作经历 2022.05 - 今助理教授，清华大学万科公共卫生与健康学院 2019.11 - 2022.4 助理研究员，清华大学医学院清华临床试验中心 2017.10 - 2019.10 博士后，清华大学-葛兰素史克（GSK）全球健康中心，清华大学 2012.09 - 2014.07 访问学者，美国匹兹堡大学医学院（UPMC）希尔曼癌症中心

研究领域

李冠乔教授课题组运用药物流行病学方法、数字健康技术，结合单细胞转录组等多组学技术，评估对治疗药物的研发、评价、监管与使用的重要问题和新兴工具。该团队致力于最大限度地提高治疗的使用、安全性和有效性，从而实现保护和促进公众健康。重点研究方向包括：1）药品有效性和安全性的定量化评价；2）生物标志物、替代终点、数字化技术等新型研发和监管工具的开发与应用；3）药品法律法规对于药物研发和使用的系统性评估；4）智能化辅助决策模型的开发，现代化药品科学评价与监管体系的构建；5）真实世界公共健康政策效果评估，解决医疗实践、疾病管理和医保花费的重要科学和管理问题。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Li G, Liu Y, Ruyi H, Su L, Chen X. (2022) FDA decisions on new oncologic drugs: China’s experience with imported drugs. Lancet Oncology;23(5):583-585. Li G*, Liu Y*, Hu H, Yuan S, Zhou L, Chen X. (2022) Evolution of innovative drug R&D in China. Nat Rev Drug Discov. 21(8):553-554. Li G, Jiang Y, Qin Y, Yuan S, Chen X. (2022) Comparing development strategies for PD-1/PD-L1-based immunotherapies. Nat Rev Drug Discov. 21(7):484. Liu Y*, Zhang N*, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H, Xie W, Zhai Q, Li G#, Chen H#, Chen X#. (2022) Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharmaceutica Sinica B. August 2022 online. Li G*, Liu Y*, Xie C, Zhou Q, Chen X. (2021) Characteristics of expedited programs on cancer drug approval in China. Nat Rev Drug Discov. 20(6):416. Li G, Qin Y, Xie C, Wu Y, Chen X. (2021) Trends in oncology drug innovation in China. Nat Rev Drug Discov. 20(1): 15-16. Bai X, Jiang S, Zhou Y, Zhen H, Ji J, Li Y, Ruan G, Yang Y, Shen K, Wang L, Li G#, Yang H#. (2021) Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 12:720776. (# corresponding authors) Li G, Liu X, Chen X. (2020) Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 17(10):589-590. Li G*, Yin C*, Zhou Y, Wang T, Chen J, Liu Y, Chen T, Wang H, Zhang L, Chen X. (2020) Digitalized Adaptation of Oncology Trials during and after COVID-19. Cancer Cell. 38(2):148-149. Li G, Sachdev U, Peters K, Liang X, Lotze MT. (2019) The VE-PTP inhibitor AKB-9778 improves anti-tumor activity and diminishes toxicity of Interleukin 2 (IL-2) administration. J Immunother.42:237-243 公共卫生与流行病学 Li G, Jiang Y, Zhang L. (2019) HIV upsurge in China's students. Science. 364(6442):711. Ge C*, Du K*, Luo M, Shen K, Zhou Y, Guo K, Liu Y, Yin C, Li Y, Li G#, Chen X# (2022). Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022;11(1):46. (# corresponding authors) Li G*, Zhou Y*, Ji J, Liu X, Jin Q, Zhang L. (2021) Surging publications on the COVID-19 pandemic. Clin Microbiol Infec.;27(3):484-486. Lv Y*, Li G*, Hu M*, Xu C*, Lu H*, Xing Y, Liang S, Ma Y, Liang S, Zhuang M, Li Y, Huang C, Bai Y, Jiang Y#, Zhang L#. (2021) Anonymous linkage between college students and facilities: systematic evaluation of urine self-collection for HIV testing initiative in China. Clin Infect Dis.;73(5):e1108-e1115. Chen T*, Huang S*, Li G*, Zhang Y, Zhu J, Shi X, Li X#, Xie G#, Zhang L#. (2021) An integrated framework for modelling quantitative effects of entry restrictions and travel quarantine on importation risk of COVID-19. J Biomed Inform. 118:103800 Sun K*, Xu L*, Li G*, Ruan X, Li X, Deng P, Li X, Li Q, Chen X, Xiong Y, Lu S, Qi L, Shen C, Tang W, Rong R, Hong B, Ning Y, Long D, Xu J, Shi X, Yang Z, Zhang Q, Zhuang Z, Zhang L#, Xiao J#, Li Y#. (2019) Forecasting Influenza Activity Using Self-Adaptive AI Model and Multi-Source Data in Chongqing, China. Ebiomedicine.47:284-292.